CD4 and myeloid sarcoma: In summary, our data indicate that MNCs derived from MS patients, who are heterozygous for a G>A substitution in exon 9 of the NOD2 gene, display enhanced CD4+ T cell proliferation and production of IL-5 and IL-17 in response to challenge with the myelin self-antigen MBP.